Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes | Zendy

Stefano Palomba | Zendy; Fabio Giuliano Numis | Zendy; Giuseppe Mossetti | Zendy; Domenico Rendina | Zendy; Pietro Vuotto | Zendy; Tiziana Russo | Zendy; Fulvio Zullo | Zendy; Carmine Nappi | Zendy; V. Nunziata | Zendy

Open Access

Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes

Author(s) -

Stefano Palomba,

Fabio Giuliano Numis,

Giuseppe Mossetti,

Domenico Rendina,

Pietro Vuotto,

Tiziana Russo,

Fulvio Zullo,

Carmine Nappi,

V. Nunziata

Publication year - 2003

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/deg031

Subject(s) - calcitriol receptor , medicine , raloxifene , osteoporosis , endocrinology , deoxypyridinoline , bone mineral , urinary system , osteocalcin , vitamin d and neurology , urology , chemistry , estrogen receptor , alkaline phosphatase , breast cancer , cancer , enzyme , biochemistry

The vitamin D receptor (VDR) gene polymorphism has been considered a factor influencing the effectiveness of the anti-osteoporotic treatments. The aim of this study was to correlate the effectiveness of raloxifene treatment in post-menopausal women with osteoporosis to BsmI VDR genotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research